Thyroid eye disease survey: An anonymous web-based survey in the Indian subcontinent.
India
orbital decompression
survey
thyroid eye disease
Journal
Indian journal of ophthalmology
ISSN: 1998-3689
Titre abrégé: Indian J Ophthalmol
Pays: India
ID NLM: 0405376
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
entrez:
26
7
2020
pubmed:
28
7
2020
medline:
15
5
2021
Statut:
ppublish
Résumé
To evaluate the current practice patterns in the treatment of thyroid eye disease (TED) in Indian subcontinent through a web-based survey of members of Oculoplastics Association of India (OPAI). This was an online web-based questionnaire survey disseminated via monkeysurvey.com to all ratified active members of OPAI between May 1, 2016 and June 30, 2016. Questions encompassed the background, training, region, and experience of oculoplastic surgeons along with the management protocol of TED. Of the 435 emails sent to OPAI members, 9 bounced and 180 (42.3%) responded within the study period. A large majority (96%) of respondents were oculoplastic surgeons practicing in India and the remaining practiced within South-East Asia. Two-thirds of respondents were oculoplastic surgeons with less than 10 years of clinical experience; 82% were fellowship trained in Oculoplasty. Almost all (99%) favored a multidisciplinary management of TED. A large majority routinely grade the severity (89%) and activity (87%) of disease before management. While corticosteroid remained the treatment of choice, 54% preferred immune-modulators as the second-line of therapy for recalcitrant TED. Three-quarters did not use orbital radiotherapy as a management modality in active TED owing to concerns over its efficacy and/or safety. The survey gives useful insights to the practice patterns of TED management in Indian subcontinent. Multidisciplinary approach and grading of disease severity and activity were the rule rather than exception among OPAI members. Immune modulation was the preferred steroid-sparing agent in recalcitrant disease. Orbital radiotherapy was an uncommon treatment choice.
Identifiants
pubmed: 32709788
pii: IndianJOphthalmol_2020_68_8_1609_290404
doi: 10.4103/ijo.IJO_1918_19
pmc: PMC7640870
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1609-1614Commentaires et corrections
Type : CommentIn
Type : CommentIn
Déclaration de conflit d'intérêts
None
Références
J Clin Endocrinol Metab. 2005 Sep;90(9):5234-40
pubmed: 15998777
Ophthalmology. 2001 Sep;108(9):1523-34
pubmed: 11535445
Ophthalmic Plast Reconstr Surg. 2015 Mar-Apr;31(2):127-31
pubmed: 24988501
N Engl J Med. 1993 Nov 11;329(20):1468-75
pubmed: 8413459
Ophthalmology. 2008 Feb;115(2):398-409
pubmed: 18082885
Thyroid. 2004 May;14(5):403-6
pubmed: 15186621
Int J Radiat Oncol Biol Phys. 1999 Mar 1;43(4):805-15
pubmed: 10098436
N Engl J Med. 2010 Feb 25;362(8):726-38
pubmed: 20181974
Thyroid. 2008 Mar;18(3):333-46
pubmed: 18341379
Br J Ophthalmol. 2004 Nov;88(11):1359-60
pubmed: 15489472
Clin Endocrinol (Oxf). 1998 Jul;49(1):21-8
pubmed: 9797843
Orbit. 2014 Oct;33(5):319-25
pubmed: 25121573
J Clin Endocrinol Metab. 2003 Aug;88(8):3561-6
pubmed: 12915636
J Clin Endocrinol Metab. 2004 Oct;89(10):5076-80
pubmed: 15472208
Indian J Ophthalmol. 2012 Mar-Apr;60(2):87-93
pubmed: 22446901
Thyroid. 2007 Apr;17(4):357-62
pubmed: 17465867
Clin Endocrinol (Oxf). 2008 Dec;69(6):951-6
pubmed: 18462263
Eye (Lond). 2013 Mar;27(3):308-19
pubmed: 23412559
Clin Endocrinol (Oxf). 2005 Sep;63(3):323-8
pubmed: 16117821
Ophthalmology. 2004 Aug;111(8):1557-62
pubmed: 15288988
Eur Thyroid J. 2016 Mar;5(1):9-26
pubmed: 27099835
Radiother Oncol. 1999 Dec;53(3):205-8
pubmed: 10660199
Lancet Diabetes Endocrinol. 2017 Aug;5(8):585-596
pubmed: 28601585
Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):192-7
pubmed: 11777638
Eur J Endocrinol. 2006 Aug;155(2):207-11
pubmed: 16868132
Radiother Oncol. 1996 Jan;38(1):69-71
pubmed: 8850428
Curr Opin Ophthalmol. 2012 Sep;23(5):427-32
pubmed: 22729183